Take Control with InsuPad®
Achieve therapeutic target with less hypoglycemia and less insulin

About Us

“It’s not often that something so small, so simple and so easy to use can bring such freedom and control to people.” Gabriel Bitton, Founder, VP R&D"

Insuline Medical is a publicly-listed Israeli medical device company (INSL.TA), which has developed, and is manufacturing and marketing a device which enables patients on intensive insulin therapy to take control of their disease and reach treatment targets in a more effective way.

Insuline Medical has been active in developing a new approach to insulin therapy care since 2007, and has developed two medical devices using similar technology. InsuPatch & InsuPad are both designed to improve the current meal-time insulin therapy.

The InsuPad, the company’s flagship product, is composed of a disposable injection window part (Fenster) and a reusable rechargeable control unit, using the innovative injection site treatment and stabilization technology. Focusing its efforts on InsuPad, Insuline succeeded in demonstrating significant clinical benefits for patients, physicians and sick-funds. 

InsuPad is non-invasive, safe, simple and easy to use, and has Medical Devices Directive (CE Mark) approval for the European Union.  

InsuPad is also approved for marketing in Israel and Canada. A US regulatory process has been initiated to confirm an FDA 510(k) de-novo application* 

Insuline have initiated commercialization in Germany in collaboration with J&J (LifeScan), and in Israel with DYN diagnostics, exclusive representatives of Roche Diagnostics in Israel.

Insuline Medical is led by experienced executives and is supported by a group of world-class medical Key Opinion Leaders.

 

*The information presented in this section in connection with the FDA approval process, for the Company's InsuPad product, is forward-looking information, as such term is defined in the Securities Law, 5728-1968, which is, inter alia, dependent on the FDA's policies and the discussions between the Company and the FDA.